May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin®) Therapy versus Verteporfin Therapy and Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • S. M. Michels
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • G. Weigert
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • W. Geitzenauer
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • S. Sacu
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • V. Alina
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • U. Schmidt-Erfurth
    Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships S.M. Michels, Novartis, R; G. Weigert, None; W. Geitzenauer, None; S. Sacu, None; V. Alina, None; U. Schmidt-Erfurth, QLT INC, P; Novartis, R.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1820. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. M. Michels, G. Weigert, W. Geitzenauer, S. Sacu, V. Alina, U. Schmidt-Erfurth; Intravitreal Bevacizumab (Avastin®) Therapy versus Verteporfin Therapy and Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1820. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To compare functional and anatomic outcomes of intravitreal Bevacizumab (Avastin®) and verteporfin therapy combined with intravitreal triamcinolone in patients with neovascular age-related macular degeneration (AMD)

Methods:: Twenty-eight patients with neovascular AMD were enrolled in a prospective, randomized, controlled clinical trial. The protocol was approved by the ethics committee at the Medical University Vienna and was registered at the European Clinical Trial Database. All patients randomized to 1 mg of intravitreal bevacizumab (0.04ml) received 3 initial treatments at 4 weeks intervals. In further follow-up retreatment was based on optical coherence tomography (OCT). Patients randomized to standard verteporfin therapy received a same day intravitreal injection of 4mg triamcinolone (Kenalog ®). Retreatment was based on fluorescein angiography (FA) at 3 months intervals. Functional and anatomic results were evaluated using the Early Treatment Diabetic Retinopathy study (ETDRS) protocol vision charts, FA and OCT.

Results:: Baseline characteristics were comparable for both groups with regard to visual acuity (ETDRS), central retinal thickness (CRT) and CNV subtyp. At month 3 visual acuity increased in the bevacizumab group from 49.6 ± 17.6 letters (~ 20/100) at baseline to 58.8 ± 19.4 letters (~20/63) and decreased slightly in the verteporfin and intravitreal triamcinolone treated group from 40.5 ± 15.9 (~20/160) to 38.6 ± 21.3 (~20/160-1). Both groups showed similar results with regard to reduction in central retinal thickness (CRT) as measured by OCT. At month 3 CRT was reduced in the bevacizumab treated group from 358µm to 225µm and in the verteporfin and intravitreal triamcinolone treated group from 328µm to 213µm.

Conclusions:: Intravitreal bevacizumab showed promising short-term results in patients with neovascular AMD. Functional results appear not only to be dependent on reduction in CRT but also on the treatment modality used.

Clinical Trial:: European Clinical Trial Database No 2005-003132-21

Keywords: age-related macular degeneration • choroid: neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×